ANI Pharmaceuticals Surges on Rare Disease Growth | Business and Finance News

ANI Pharmaceuticals is crushing it—reporting record $266M Q2 revenue, driven by Cortrophin’s $117M haul and a 50% sales force expansion to 180 reps targeting gout. With 43% YoY growth in Cortrophin and strong demand in rheumatology and neurology, the company is poised for $520M–$540M in Cortrophin revenue this year. Generics are also firing on all cylinders, launching 12 new products with 15 on track. Rare disease now accounts for nearly 60% of projected $1B+ annual revenue, fueling aggressive inorganic growth plans. ANI’s strategy? Become the rare disease leader—with a healthy balance sheet and acquisition radar firmly aimed at expanding its portfolio. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9a19d715793dde28